PROTAC Aurora A Degrader-1
PROTAC Aurora A Degrader-1 is an orally active and blood-brain barrier-permeable selective Aurora A PROTAC degrader. PROTAC Aurora A Degrader-1 induces AURKA degradation with a DC50 of 6 nM in IMR32 cells (Dmax = 95%), eliminates both the kinase catalytic activity and N-Myc stabilizing scaffolding function of Aurora A, induces DNA damage, G2/M arrest and apoptosis, and shows antiproliferative activity. PROTAC Aurora A Degrader-1 is applicable to the research of neuroblastoma and small cell lung cancer.
(Pink: Aurora A ligand (HY-10971); Blue: Cereblon ligand (HY-103597); Black: linker).
For research use only. We do not sell to patients.
- CAS No.: 3115344-59-4
- Formula: C38H43ClN10O3
- Molecular Weight:723.27
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
Aurora A |
Cereblon |
In Vitro
PROTAC Aurora A Degrader-1 (compound 280) (0.1-1000 nM; 24 h) induces concentration-dependent degradation of endogenous Aurora A in MYCN-amplified neuroblastoma with DC50 = 6 nM and Dmax = 95%[1].
PROTAC Aurora A Degrader-1 (serial concentration gradient; 7 days) dose-dependently suppresses proliferation of MV4-11, IMR32, SK-N-BE(2) neuroblastoma and SCLC cells, with GI50 values as low as 5.6 nM (H82 SCLC cell line)[1].
PROTAC Aurora A Degrader-1 (3 μM; 1-48 h) achieves obvious Aurora A degradation starting at 2 h of treatment[1].
PROTAC Aurora A Degrader-1 (3 μM; 24 h) reduces intracellular N-Myc protein level by eliminating Aurora A scaffolding function for N-Myc stabilization, without changing MYCN mRNA transcription[1].
PROTAC Aurora A Degrader-1 (0.5-3 μM; 24-48 h) triggers G2/M cell cycle arrest and tumor cell apoptosis, upregulates cleaved Caspase-3 and cleaved PARP protein expression, and elevates intracellular DNA damage response level[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:SK-N-BE(2), IMR32, SCLC
-
Concentration:0.1, 1, 10, 100, 1000 nM
-
Incubation Time:24 h
-
Result:Induced concentration-dependent degradation of endogenous Aurora A in MYCN-amplified neuroblastoma with DC50 = 6 nM and Dmax = 95%.
-
Cell Line:SK-N-BE(2), SCLC
-
Concentration:0.5, 1, 3 μM
-
Incubation Time:24-48 h
-
Result:Triggered G2/M cell cycle arrest and tumor cell apoptosis, upregulates cleaved Caspase-3 and cleaved PARP protein expression, and elevates intracellular DNA damage response level.
Parmacokinetics
| Species | Dose | Route | CL | Vss | T1/2 | C0 | AUClast | Cmin | Tmax | Cmax | F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mice[1] | 1 mg/kg | i.v. | 17.5 mL/min/kg | 4.78 L/kg | 5.51 h | 498 ng/mL | 928 ng·h/mL | 3.52 ng/mL | / | / | / |
| Rat[1] | 1 mg/kg | i.v. | 27 mL/min/kg | 3.12 L/kg | 3.20 h | 596 ng/mL | 620 ng·h/mL | 0.26 ng/mL | / | / | / |
| Dog[1] | 1 mg/kg | i.v. | 14 mL/min/kg | 12 L/kg | 13 h | 382 ng/mL | 917 ng·h/mL | 11.4 ng/mL | / | / | / |
| Mice[1] | 10 mg/kg | p.o. | / | / | / | / | 5410 ng·h/mL | 6.54 ng/mL | 1 h | 796 ng/mL | 58 % |
| Rat[1] | 10 mg/kg | p.o. | / | / | / | / | 4514 ng·h/mL | 4.70 ng/mL | 8 h | 365 ng/mL | 73 % |
| Dog[1] | 10 mg/kg | p.o. | / | / | / | / | 10091 ng·h/mL | 197 ng/mL | 4.67 h | 916 ng/mL | 71 % |
In Vivo
PROTAC Aurora A Degrader-1 significantly inhibits tumor volume growth and prolongs overall survival of neuroblastoma and SCLC xenograft mice, achieves durable tumor regression and extends survival in IMR-32 models, extends median survival to 34 days compared to 17 days for the AURKA inhibitor LY3295668 (HY-114258) and vehicle control in H82 SCLC models, and shows no significant body weight loss or severe myelosuppression[1].
PROTAC Aurora A Degrader-1 reduces Aurora A levels and the expression of Ki67 proliferation marker, while increasing levels of DNA damage markers and apoptotic proteins in tumor lesions[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:IMR32 Neuroblastoma Xenograft[1]
-
Dosage:60 mg/kg
-
Administration:p.o.; once daily
-
Result:Induced rapid and sustained AURKA degradation.
Reduced phosphorylated Aurora A and N-Myc protein in tumor tissue.
Induced sustained DNA damage and G2/M arrest.
Triggered massive tumor cell apoptosis.
-
Animal Model:H82 SCLC Xenograft[1]
-
Dosage:60 mg/kg
-
Administration:p.o.; once daily
-
Result:Inhibited tumor volume growth and prolongs overall survival.
Achieved durable tumor regression.
Extended median survival to 34 days compared to 17 days for the AURKA inhibitor LY3295668 and vehicle control.
Showsed no significant body weight loss or severe myelosuppression.
Chemical Information
-
CAS No. 3115344-59-4
-
Molecular Weight 723.27
-
Formula C38H43ClN10O3
-
SMILES
CC1=NN(C=C1C2=NC3=C(N2)N=CC(Cl)=C3OC4=CC=C(C=C4)N5CCN(C[C@@H]5C)CC6CCN(CC6)C7=CC=C(C=C7)N8CCC(NC8=O)=O)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Genotoxicity/Mutagenicity Study
The bacterial reverse mutation assay detects point mutations that restore amino-acid prototrophy in auxotrophic Salmonella typhimurium or Escherichia coli tester strains; after exposure to a test article, mutagenic activity is read out as an increased number of revertant colonies on minimal agar compared with the vehicle control. The assay uses tester strains with different mutation targets so that base-substitution and frameshift mutagens can be detected, and testing is performed with and without exogenous mammalian metabolic activation because some chemicals require biotransformation to become mutagenic.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)